Allergies and Marketing - Clinical Research Informer

Peanut Allergy Market Outlook: The Market Size Growth Sees Major Thrusts

Delveinsight

AUGUST 2, 2021

Peanut allergy (PA) is one of the most common food allergies that affect children in Western nations. Historically, the gold standard of the treatment for Peanut allergy constituted a strategic plan for peanut avoidance coupled with an adrenaline auto-injector (AAI) in case of contingencies.

Allergies

Allergies Marketing Development Trials

NICE backs Aimmune’s peanut allergy drug Palforzia for children

pharmaphorum

DECEMBER 23, 2021

Children in England with peanut allergies could be among the first in Europe to get access to Aimmune’s oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS England. billion last year, is also developing immunotherapies for other indications including egg and multi-tree nut allergies.

Allergies

Allergies Drugs Clinical Trials Clinical Trials

FDA approves Roche, Novartis' Xolair to prevent severe outcomes from common food allergies

Fierce Pharma

FEBRUARY 16, 2024

People with food allergies finally have a drug that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades. People with food allergies finally have a drug that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades.

Allergies

Allergies FDA Approval Marketing Medicine

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Roche, Novartis move Xolair closer to FDA finish line for food allergies

Fierce Pharma

DECEMBER 19, 2023

On the market for two decades for asthma, Novartis and Roche’s Xolair is closing in on a new indication as a way for those with food allergies to avoid severe outcomes. | The agency granted a priority review to Roche's filing and plans to make a decision during the first quarter of next year.

Allergies

Allergies Marketing

How the food allergy sector is benefitting from health tech’s recent boom

pharmaphorum

OCTOBER 10, 2022

For the 32 million individuals in the US with food allergies, more research into symptoms, causes, and treatments has been long sought after, but historically underfunded. per person being spent on food allergy research. Luckily for those with food allergies, the food allergy sector has benefitted from this influx of funding.

Allergies

Allergies Marketing Production Doctor

FDA approves IND application for peanut allergy drug candidate

Outsourcing Pharma

SEPTEMBER 16, 2021

The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.

Allergies

Allergies FDA Approval Drugs Regulation

Asthma Drug Xolair Wins FDA Approval as First Treatment for Multiple Food Allergies

XTalks

FEBRUARY 26, 2024

The class of IgE-mediated food allergies includes 160 foods, with peanuts, milk, eggs, wheat, soy and tree nuts being the most common ones. According to the Centers for Disease Control and Prevention (CDC), almost six percent of people in the US in 2021 had a food allergy. However, the treatment is restricted to peanut allergy.

Allergies

Allergies FDA Approval Drugs Protein

COVID-19 vaccines and allergies: Updated advice needs to reach a wider audience, says BMJ

BioPharma Reporter

JANUARY 18, 2021

At the end of December, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) updated its advice on the Pfizer/BioNTech vaccine: saying that those with unrelated allergies could receive it. But this announcement did not receive as much coverage as the MHRAâs earlier pause on vaccination in people with allergies.

Allergies

Allergies Vaccine Vaccination Medicine

Omlyclo Becomes First Biosimilar to Rival Xolair

XTalks

MARCH 10, 2025

Originally approved by the FDA over two decades ago for the treatment of moderate to severe persistent asthma, Xolair recently also gained approval for managing food allergies. The OUtMATCH study, conducted in patients with food allergies, found that Xolair may be more effective and better tolerated than OIT. billion by 2030.

Allergies

Allergies FDA Approval Antibody Trials

RVAC and University of Pennsylvania to develop mRNA vaccines

Pharmaceutical Technology

MARCH 20, 2023

The partnership will focus on developing potential new vaccines to treat certain selected autoimmune indications, as well as food allergies. RVAC Medicines chief scientific officer Dr Jason Zhang said: “We are very glad to work with Dr Weissman on potential mRNA treatment approaches for a broad spectrum of allergy and autoimmune diseases.

Vaccine

Vaccine Vaccination Development Allergies

GreenLight and US NIH partner to develop Covid-19 vaccine for variants

Pharmaceutical Technology

AUGUST 1, 2022

The company will jointly design and analyse messenger ribonucleic acid (mRNA) Covid-19 vaccines in partnership with the NIH unit National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC). They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccine

Vaccine Vaccination Development RNA

Allergy Treatment Market Report 2021: Analysis By Allergy Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergies, and Other Allergies); Treatment (Anti-Allergy Drugs, and Immunotherapy) – ResearchAndMarkets.com

BioTech 365

APRIL 27, 2021

Allergy Treatment Market Report 2021: Analysis By Allergy Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergies, and Other Allergies); Treatment (Anti-Allergy Drugs, and Immunotherapy) – ResearchAndMarkets.com Allergy Treatment Market Report 2021: Analysis By Allergy Type (Eye Allergy, Rhinitis, Asthma, … Continue reading → (..)

Allergies

Allergies Marketing Drugs

New patent for Glaxosmithkline Cons drug FLONASE SENSIMIST ALLERGY RELIEF

Drug Patent Watch

FEBRUARY 12, 2024

Annual Drug Patent Expirations for FLONASE+SENSIMIST+ALLERGY+RELIEF Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. There… The post New patent for Glaxosmithkline Cons drug FLONASE SENSIMIST ALLERGY RELIEF appeared first on DrugPatentWatch - Make Better Decisions.

Allergies

Allergies Drugs Marketing

Allergy specialist Stallergenes taps Aptar for digital delivery

pharmaphorum

OCTOBER 27, 2021

AIT involves the administration of controlled, low doses of allergens under the tongue or by subcutaneous injection in people with allergies, with the aim of desensitising the immune system to them and prevent allergic reactions. ” The post Allergy specialist Stallergenes taps Aptar for digital delivery appeared first on.

Allergies

Allergies Drug Delivery Development Marketing

New patent for Bayer Hlthcare drug ASTEPRO ALLERGY

Drug Patent Watch

AUGUST 24, 2021

Annual Drug Patent Expirations for ASTEPRO+ALLERGY Astepro Allergy is a drug marketed by Bayer Hlthcare and is included in one NDA. The generic ingredient in ASTEPRO ALLERGY is azelastine hydrochloride.….

Allergies

Allergies Drugs Marketing

New patent for Bayer Hlthcare drug ASTEPRO ALLERGY

Drug Patent Watch

AUGUST 14, 2021

Annual Drug Patent Expirations for ASTEPRO+ALLERGY Astepro Allergy is a drug marketed by Bayer Hlthcare and is included in one NDA. The generic ingredient in ASTEPRO ALLERGY is azelastine hydrochloride.….

Allergies

Allergies Drugs Marketing

New Xolair TV Commercials Say, ‘Accidents Happen’ When It Comes to Food Allergies

XTalks

SEPTEMBER 27, 2024

Novartis and Genentech released a pair of new TV commercials for allergy and asthma drug Xolair (omalizumab) as part of a direct-to-consumer (DTC) nationwide campaign called “Accidents Happen.” The ad highlights that despite the care parents take in handling their children’s allergies, accidental exposure can happen.

Allergies

Allergies Marketing FDA Approval Drugs

New patent expiration for Glaxosmithkline Cons drug FLONASE SENSIMIST ALLERGY RELIEF

Drug Patent Watch

AUGUST 2, 2021

Annual Drug Patent Expirations for FLONASE+SENSIMIST+ALLERGY+RELIEF Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. The post New patent expiration for Glaxosmithkline Cons drug FLONASE SENSIMIST ALLERGY RELIEF appeared first on DrugPatentWatch - Make Better Decisions.

Allergies

Allergies Drugs Marketing

STAT+: Thirty Madison, looking to stand out in a crowded telehealth market, quietly plans expansion into sleep care

STAT News

DECEMBER 5, 2022

In the fight to command the growing market for telehealth, Thirty Madison is staking out new terrain. Over the last year and a half, the 5-year-old digital health startup has been quietly planning to expand into sleep care with a new brand called River. Continue to STAT+ to read the full story…

Marketing

Marketing Allergies Pharmacy Branding

Allergy Immunotherapies Market – Actionable Research on COVID-19 | Increasing Prevalence of Allergies to Boost the Market Growth | Technavio

BioTech 365

OCTOBER 7, 2020

LONDON–(BUSINESS WIRE)–#AllergyImmunotherapiesMarket–The global allergy immunotherapies market size is poised to grow by USD 626.77 million during 2020-2024, progressing at a CAGR of about 7% throughout the forecast period, according to the latest report by Technavio.

Allergies

Allergies Marketing Research

Moderna is corporate greed at its worst

World of DTC Marketing

NOVEMBER 19, 2021

In 2015, the National Institute of Allergy and Infectious Diseases, an institute within the NIH, signed a cooperative R&D agreement with Moderna on basic research, including new vaccines. Additionally, Moderna used patents and non-exclusive rights that the U.S. government made available to them to make this COVID-19 vaccine.

Vaccination

Vaccination Vaccine Allergies Production

New patent expiration for Sanofi Aventis drug ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

Drug Patent Watch

DECEMBER 24, 2020

Annual Drug Patent Expirations for ALLEGRA-D+24+HOUR+ALLERGY+AND+CONGESTION Allegra-d 24 Hour Allergy And Congestion is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from….

Allergies

Allergies Drugs Marketing

European Allergy Immunotherapies Market Forecast to 2027- COVID-19 Impact and Analysis – ResearchAndMarkets.com

BioTech 365

NOVEMBER 6, 2020

European Allergy Immunotherapies Market Forecast to 2027- COVID-19 Impact and Analysis – ResearchAndMarkets.com European Allergy Immunotherapies Market Forecast to 2027- COVID-19 Impact and Analysis – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Europe Allergy Immunotherapies Market Forecast to 2027- COVID-19 Impact (..)

Allergies

Allergies Marketing

Camallergy’s UK Based Manufacturing Facility Receives cGMP Licences for Peanut Allergy Treatment

The Pharma Data

JANUARY 7, 2021

This clearance is a pivotal regulatory milestone that further supports Camallergy’s leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy,” said Sherden Timmins, Chief Technology Officer. 8, 2021 07:00 UTC. About Camallergy.

Allergies

Allergies Manufacturing Production Clinical Trials

DBV craters on FDA’s peanut allergy immunotherapy rejection

pharmaphorum

AUGUST 5, 2020

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end. The rationale behind Viaskin Peanut is to expose people with peanut allergy to small, rising amounts of peanut protein – which acts as an allergen – to encourage the immune system to develop tolerance over time.

Allergies

Allergies Production Clinical Trials Clinical Trials

Global Allergy Immunotherapy (AIT) Market to 2024 – Size & Forecast with Impact Analysis of COVID-19 – ResearchAndMarkets.com

BioTech 365

NOVEMBER 25, 2020

Global Allergy Immunotherapy (AIT) Market to 2024 – Size & Forecast with Impact Analysis of COVID-19 – ResearchAndMarkets.com Global Allergy Immunotherapy (AIT) Market to 2024 – Size & Forecast with Impact Analysis of COVID-19 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Allergy … (..)

Allergies

Allergies Marketing

Merck gives taxpayers the middle finger

World of DTC Marketing

OCTOBER 6, 2021

Like the vast majority of medicines on the market, molnupiravir — which was originally investigated as a possible treatment for Venezuelan equine encephalitis — was developed using government funds. The Intercept. Merck is not alone in hosing taxpayers.

Clinical Trials

Clinical Trials Clinical Trials Allergies Trials

Global Allergy & Immunology Market Research Report 2021-2026: Extensive R&D for Immunotherapy Solutions Against Food Allergens – ResearchAndMarkets.com

BioTech 365

JULY 20, 2021

Global Allergy & Immunology Market Research Report 2021-2026: Extensive R&D for Immunotherapy Solutions Against Food Allergens – ResearchAndMarkets.com Global Allergy & Immunology Market Research Report 2021-2026: Extensive R&D for Immunotherapy Solutions Against Food Allergens – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)

Allergies

Allergies Marketing Research

Global Anti-Allergy Drugs Market Report 2021: Market to Reach $39.3 Billion by 2027 – U.S. Market is Estimated at $6.7 Billion, While China is Forecast to Grow at 10.5% CAGR – ResearchAndMarkets.com

BioTech 365

MARCH 9, 2021

Global Anti-Allergy Drugs Market Report 2021: Market to Reach $39.3 Market is Estimated at $6.7 CAGR – ResearchAndMarkets.com Global Anti-Allergy Drugs Market Report 2021: Market to … Continue reading → Billion by 2027 – U.S. Billion, While China is Forecast to Grow at 10.5%

Allergies

Allergies Marketing Drugs

Global Allergy Diagnostic and Treatment Market (2021 to 2029) – Featuring bioMerieux, Siemens Healthcare and Danaher Among Others – ResearchAndMarkets.com

BioTech 365

JUNE 14, 2021

Global Allergy Diagnostic and Treatment Market (2021 to 2029) – Featuring bioMerieux, Siemens Healthcare and Danaher Among Others – ResearchAndMarkets.com Global Allergy Diagnostic and Treatment Market (2021 to 2029) – Featuring bioMerieux, Siemens Healthcare and Danaher Among Others – ResearchAndMarkets.com … Continue (..)

Allergies

Allergies Marketing

Global Ragweed Pollen Allergy Treatment Market to be valued at US$ 1,147.3 Million by 2027, Says Coherent Market Insights (CMI)

BioTech 365

AUGUST 10, 2020

SEATTLE–(BUSINESS WIRE)–#RagweedPollenAllergyTreatment–According to Coherent Market Insights, the global ragweed pollen allergy treatment market is estimated to be valued at US$ 836.9 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027).

Allergies

Allergies Marketing

Allergy Rhinitis Drugs Market – Actionable Research on COVID-19 | Growing Awareness about Allergic Rhinitis to Boost the Market Growth | Technavio

BioTech 365

OCTOBER 7, 2020

LONDON–(BUSINESS WIRE)–#AllergyRhinitisDrugsMarket–The global allergy rhinitis drugs market size is poised to grow by USD 2.4 billion during 2020-2024, progressing at a CAGR of almost 4% throughout the forecast period, according to the latest report by Technavio.

Allergies

Allergies Marketing Drugs Research

Global Rx-to-OTC Switches Market Landscape 2021-2031 – Allergy & Respiratory Drugs Anticipated to Gain a Revenue Share of More Than 25% – ResearchAndMarkets.com

BioTech 365

DECEMBER 15, 2021

Global Rx-to-OTC Switches Market Landscape 2021-2031 – Allergy & Respiratory Drugs Anticipated to Gain a Revenue Share of More Than 25% – ResearchAndMarkets.com Global Rx-to-OTC Switches Market Landscape 2021-2031 – Allergy & Respiratory Drugs Anticipated to Gain a Revenue Share … Continue reading →

Allergies

Allergies Marketing Drugs

Donidalorsen Shows Sustained HAE Attack Reduction According to New Trial Data

XTalks

FEBRUARY 24, 2025

Carlsbad, California-based Ionis Pharmaceuticals announced it will be sharing promising new trial data for its RNA-targeted prophylactic treatment donidalorsen for hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, California.

Trials

Trials RNA Allergies Drugs

Juno Pharmaceuticals buys Omega Laboratories

Pharmaceutical Technology

MAY 16, 2023

The firm plans to offer more than 100 new products to the Canadian market in the next four years, with pain management, oral solutions, allergy vaccines, diabetes and weight loss as the main areas of focus. The deal allows Juno to provide medical practitioners and patients with new critical pharmaceutical products.

Cosmetics

Cosmetics Allergies Manufacturing Production

The Worldwide Allergy Diagnostics Industry is Expected to Reach $8.2 Billion by 2026 – ResearchAndMarkets.com

BioTech 365

NOVEMBER 17, 2021

The Worldwide Allergy Diagnostics Industry is Expected to Reach $8.2 Billion by 2026 – ResearchAndMarkets.com The Worldwide Allergy Diagnostics Industry is Expected to Reach $8.2

Allergies

Allergies Production Marketing

What role does health literacy play in clinical trial participation?

Antidote

SEPTEMBER 1, 2023

As part of our efforts to better understand patients and their motivations to participate in clinical trials, Antidote and SCORR Marketing partnered on a survey to gain a deeper understanding of how patients think about the medical research process.

Clinical Trials

Clinical Trials Clinical Trials Trials Allergies

Is Seed-Based the New Plant-Based?

XTalks

JUNE 23, 2021

Seed-based foods are not only allergy-friendly but also have a strong nutritional profile, loaded with protein, vitamins and minerals. Chicago-based startup Blake’s Seed Based was founded in 2018 by Blake Sorenson, an athlete with a deathly nut allergy who was looking for an alternative to nut-containing snacks. Blake’s Seed Based.

Allergies

Allergies Containment Production Branding

Partake Foods Allergen-Friendly Snacks + Imagindairy Cow-Free Milk – Xtalks Food Podcast Ep. 50

XTalks

MARCH 3, 2022

Food allergies are becoming more and more common, but that doesn’t mean those with allergies can’t enjoy a sweet treat. The team is eager to try this new type of milk and wonders whether it will be the best milk alternative — in flavor, texture and appearance — when it finally hits the market. .

Allergies

Allergies Branding Protein Production

Top New Prescription Drug Commercials on TV 2023

XTalks

SEPTEMBER 28, 2023

Related: Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate Bayer’s new over-the-counter (OTC) cold, flu and allergy med Astepro not only emerged as the most viewed new pharma TV ad in the first half of the year, but also topped iSpot.tv’s list of all new brand ads with 7.4

Drugs

Drugs Allergies Branding FDA Approval

Polyrizon IPO Strengthens Momentum in Non-Invasive Drug Delivery Solutions

XTalks

NOVEMBER 5, 2024

Trading began on the Nasdaq Capital Market under the ticker “PLRZ” on October 29, 2024. Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

Drug Delivery

Drug Delivery Drugs Immune Response Allergies

Novartis said to be eyeing sale of ophthalmology, respiratory units

pharmaphorum

NOVEMBER 16, 2022

Novartis’ respiratory and allergy business, meanwhile, is headed by Xolair (omalizumab) for severe asthma nasal polyps and chronic idiopathic urticaria (CIA) – another blockbuster also partnered with Roche. Novartis has said it will not comment on market speculation.

Sales

Sales Gene Therapy Allergies Medicine

Audience Targeting in Pharma Marketing: Reaching the Right Patients and Providers

Pharma Marketing Network

DECEMBER 19, 2024

In pharma marketing, targeting the right patients and providers ensures that every dollar spent delivers value, engagement, and, most importantly, trust. Whether youre promoting a groundbreaking oncology drug or a common allergy medication, identifying and reaching the right audience can transform outcomes.

Marketing

Marketing Compliance Branding Allergies

MHRA warns of serious eye-related adverse events after Dupixent use

Pharmaceutical Technology

DECEMBER 7, 2022

Sanofi and Regeneron’s Dupixent had previously been linked to conjunctivitis, an eye condition usually caused by allergies or an infection. Despite these concerns, GlobalData anticipates that Sanofi and Regeneron’s strong positions in the allergic diseases market will be unaffected.

Production

Production Regulation Clinical Trials Clinical Trials

Peanut Allergy Market Outlook: The Market Size Growth Sees Major Thrusts

NICE backs Aimmune’s peanut allergy drug Palforzia for children

Webinars

Trending Sources

FDA approves Roche, Novartis' Xolair to prevent severe outcomes from common food allergies

Webinars

Roche, Novartis move Xolair closer to FDA finish line for food allergies

How the food allergy sector is benefitting from health tech’s recent boom

FDA approves IND application for peanut allergy drug candidate

Asthma Drug Xolair Wins FDA Approval as First Treatment for Multiple Food Allergies

COVID-19 vaccines and allergies: Updated advice needs to reach a wider audience, says BMJ

Omlyclo Becomes First Biosimilar to Rival Xolair

RVAC and University of Pennsylvania to develop mRNA vaccines

GreenLight and US NIH partner to develop Covid-19 vaccine for variants

Allergy Treatment Market Report 2021: Analysis By Allergy Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergies, and Other Allergies); Treatment (Anti-Allergy Drugs, and Immunotherapy) – ResearchAndMarkets.com

New patent for Glaxosmithkline Cons drug FLONASE SENSIMIST ALLERGY RELIEF

Allergy specialist Stallergenes taps Aptar for digital delivery

New patent for Bayer Hlthcare drug ASTEPRO ALLERGY

New patent for Bayer Hlthcare drug ASTEPRO ALLERGY

New Xolair TV Commercials Say, ‘Accidents Happen’ When It Comes to Food Allergies

New patent expiration for Glaxosmithkline Cons drug FLONASE SENSIMIST ALLERGY RELIEF

STAT+: Thirty Madison, looking to stand out in a crowded telehealth market, quietly plans expansion into sleep care

Allergy Immunotherapies Market – Actionable Research on COVID-19 | Increasing Prevalence of Allergies to Boost the Market Growth | Technavio

Moderna is corporate greed at its worst

New patent expiration for Sanofi Aventis drug ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

European Allergy Immunotherapies Market Forecast to 2027- COVID-19 Impact and Analysis – ResearchAndMarkets.com

Camallergy’s UK Based Manufacturing Facility Receives cGMP Licences for Peanut Allergy Treatment

DBV craters on FDA’s peanut allergy immunotherapy rejection

Global Allergy Immunotherapy (AIT) Market to 2024 – Size & Forecast with Impact Analysis of COVID-19 – ResearchAndMarkets.com

Merck gives taxpayers the middle finger

Global Allergy & Immunology Market Research Report 2021-2026: Extensive R&D for Immunotherapy Solutions Against Food Allergens – ResearchAndMarkets.com

Global Anti-Allergy Drugs Market Report 2021: Market to Reach $39.3 Billion by 2027 – U.S. Market is Estimated at $6.7 Billion, While China is Forecast to Grow at 10.5% CAGR – ResearchAndMarkets.com

Global Allergy Diagnostic and Treatment Market (2021 to 2029) – Featuring bioMerieux, Siemens Healthcare and Danaher Among Others – ResearchAndMarkets.com

Global Ragweed Pollen Allergy Treatment Market to be valued at US$ 1,147.3 Million by 2027, Says Coherent Market Insights (CMI)

Allergy Rhinitis Drugs Market – Actionable Research on COVID-19 | Growing Awareness about Allergic Rhinitis to Boost the Market Growth | Technavio

Global Rx-to-OTC Switches Market Landscape 2021-2031 – Allergy & Respiratory Drugs Anticipated to Gain a Revenue Share of More Than 25% – ResearchAndMarkets.com

Donidalorsen Shows Sustained HAE Attack Reduction According to New Trial Data

Juno Pharmaceuticals buys Omega Laboratories

The Worldwide Allergy Diagnostics Industry is Expected to Reach $8.2 Billion by 2026 – ResearchAndMarkets.com

What role does health literacy play in clinical trial participation?

Is Seed-Based the New Plant-Based?

Partake Foods Allergen-Friendly Snacks + Imagindairy Cow-Free Milk – Xtalks Food Podcast Ep. 50

Top New Prescription Drug Commercials on TV 2023

Polyrizon IPO Strengthens Momentum in Non-Invasive Drug Delivery Solutions

Novartis said to be eyeing sale of ophthalmology, respiratory units

Audience Targeting in Pharma Marketing: Reaching the Right Patients and Providers

MHRA warns of serious eye-related adverse events after Dupixent use

Stay Connected